Lactobacillus Plantarum DR7 for Gut-Brain-Axis Benefits
NCT ID: NCT03370458
Last Updated: 2018-07-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
118 participants
INTERVENTIONAL
2017-12-01
2018-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Lactobacillus Plantarum P8 for Its Brain Health Promotion Potential
NCT03268447
Probiotic Intervention on Gut Microbiota and Cognitive Functioning in Older Adults With a Mild Cognitive Impairment
NCT05859230
Effects of Lactobacillus Casei on Respiratory and Gastrointestinal Diseases in Adults
NCT02541539
Gut-brain Axis, Brain Function, and Behaviour.
NCT03554694
The Cognitive Effects of 6 Weeks Administration With a Probiotic
NCT03601559
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Lactobacillus plantarum DR7 was isolated from fresh cow's milk in Penang, Malaysia. In-vitro evaluation has shown that this putative probiotic strain adhere to the criteria of probiotic characteristics; a) resistant towards acid and bile conditions of the upper gastrointestinal tract, b) does not possess antibiotic resistance as per requirement of the European Food Safety Authority (EFSA), c) able to adhere to mucin, d) has antioxidant properties, e) able to utilize prebiotics such as fructooligosaccharide (FOS), inulin and galactooligosaccharide (GOS), e) has a carbon metabolism profile adhering to the general patterns of lactobacilli, and f) possess antimicrobial properties against gastrointestinal pathogens. In-vivo evaluation using rats shown that this putative probiotic strain has gut protection properties; a) modulation of gastrointestinal microbial profile via suppressing gut pathogen populations and increasing the population of lactobacilli, b) decreasing pro-inflammatory cytokines and increasing anti-inflammatory cytokines in the plasma, and c) reducing inflammation in the lower intestines.
All these indicated that Lactobacillus plantarum DR7 has the potential to be an effective probiotic strain that modulate gut health and immunity. In addition, due to the alleviation of gastrointestinal stress, this strain may be beneficial along the gut-brain-axis to promote brain health as well.
Lactobacillus plantarum DR7 and placebo are produced under GMP and HALAL certified manufacturing facility. Probiotic Lactobacillus plantarum DR7 appears as light yellow powder. Sachets are stored away from direct sunlight and in below 30C according to the storage condition recommendations of the manufacturer. Each dose was supplied in an aluminium sachet and all sachets are identical in taste and appearance. Probiotic Lactobacillus plantarum DR7 does not contain any porcine or bovine ingredients.
The product contains Lactobacillus plantarum DR7 and maltodextrin as excipient while placebo contains only maltodextrin.
A total number of 124 healthy adults from age 18 -60 years old will be recruited for this study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lactobacillus plantarum DR7
Intervention consists of daily administration of 2g probiotic Lactobacillus plantarum DR7, administered daily at a fixed dosage of 9 log CFU/sachet/day and continue for 12 weeks.
Intervention: Dietary Supplement: Lactobacillus plantarum DR7
Lactobacillus plantarum DR7
This project aims to study the benefits of probiotics namely Lactobacillus plantarum DR7 for brain health benefits primarily to alleviate stress, among adults in Malaysia aged from 18-60 years. Secondary emphases include respiratory and gastrointestinal health
Placebo
Intervention consists of daily administration of 2g placebo (no probiotic bacteria), administered daily and continue for 12 weeks.
Intervention: Dietary Supplement: Placebo
Placebo
This project aims to study the benefits of probiotics namely Lactobacillus plantarum DR7 for brain health benefits primarily to alleviate stress, among adults in Malaysia aged from 18-60 years. Secondary emphases include respiratory and gastrointestinal health
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lactobacillus plantarum DR7
This project aims to study the benefits of probiotics namely Lactobacillus plantarum DR7 for brain health benefits primarily to alleviate stress, among adults in Malaysia aged from 18-60 years. Secondary emphases include respiratory and gastrointestinal health
Placebo
This project aims to study the benefits of probiotics namely Lactobacillus plantarum DR7 for brain health benefits primarily to alleviate stress, among adults in Malaysia aged from 18-60 years. Secondary emphases include respiratory and gastrointestinal health
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18-60 years old
* Willing to commit throughout the experiment
* Have moderate stress and beyond, as per determined by PSS test
Exclusion Criteria
* Long term medication due to certain severe illness (certain medications may interfere with the survivability of Lactobacillus in the gut, for example the interactions between probiotics and warfarin
* HIV/AIDS (there has been no substantial data on the detrimental effects of probiotics on AIDS patients. However, AIDS patient may be immune-compromised in the sense of "leaky gut" that may lead to bacterial translocation, including translocation of Lactobacillus outside the gut environment, into the blood stream)
* Glucose-6-phosphate dehydrogenase (G6PD) deficiency (there has been no substantial data on the detrimental effects of probiotics on G6PD deficiency people. However, certain strains of probiotics have been reported to benefit RBC irregularity disorders such as spur cells formation. One of the main mechanisms, involve the alteration of RBC membrane. Although this is a benefit, we are unsure of the effects on G6PD deficiency people, with weaker RBC).
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Clinical Nutrition Sdn Bhd
UNKNOWN
Universiti Sains Malaysia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Min-Tze LIONG
Professor Dr.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
MT Liong, PhD
Role: PRINCIPAL_INVESTIGATOR
Universiti Sains Malaysia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
School of Industrial Technology, Universiti Sains Malaysia
Pulau Pinang, Pulau Pinang, Malaysia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
USM/JEPeM/17040228
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.